MRK in-licenses an experimental lipoprotein(a) inhibitor from China's Jiangsu Hengrui. This transaction is expected to be ...

We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...

FairJourney Biologics S.A., global leader in antibody discovery and development, today announced the formation of its Supervisory Board to support the Company's ongoing strategy for growth and ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

Immunoglobulins sample vast swathes of primary sequence and conformational space to generate and select B cell clones with exquisite selectivity and affinity for specific antigens. This ...

After spending years unsuccessfully attempting to develop a Covid-19 vaccine, Inovio is now reporting promising results from early testing of an experimental Covid treatment.

MICVO is a first-in-concept antibody-drug conjugate antibody-drug conjugate (ADC ... Initiated Phase 1/2 combination study of micvotabart pelidotin and Merck’s anti-PD-1 therapy, KEYTRUDA ® ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...